Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) induces profound shifts in the intestinal bacterial microbiota. The dynamics of intestinal fungi and their impact on clinical outcomes have not yet been integrated into a model of microbiota function during allo-HCT. Here, we combined parallel high-throughput fungal ITS1 amplicon sequencing, bacterial 16S amplicon sequencing, and fungal cultures to reveal striking trans-kingdom dynamics and their association with patient outcomes. We saw that the overall density and the biodiversity of intestinal fungi were stable during allo-HCT, but the species composition changed drastically from day to day. We identified a subset of patients with fungal dysbiosis characterized by culture positivity, stable expansion of Candida parapsilosis complex species, and distinct trans-kingdom microbiota profiles. These patients had worse overall survival and higher transplant-related mortality independent of candidemia. Our data expand the clinical significance of the mycobiota and suggest that targeting fungal dysbiosis may help to improve long-term patient survival.
Competing Interest Statement
Jonathan U. Peled reports research funding, intellectual property fees, and travel reimbursement from Seres Therapeutics, and consulting fees from DaVolterra, CSL Behring, and from Maat Pharma. He has filed intellectual property applications related to the microbiome (reference numbers #62/843,849, #62/977,908, and #15/756,845). Marcel R.M. van den Brink has received research support from Seres Therapeutics; has consulted, received honorarium from or participated in advisory boards for Seres Therapeutics, WindMIL Therapeutics, Rheos, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Forty Seven Inc., Priothera, Ceramedix, Lygenesis, Pluto Immunotherapeutics, Magenta Therapeutics, Merck & Co, Inc., and DKMS Medical Council (Board); has IP Licensing with Seres Therapeutics, Juno Therapeutics, and stock options from Seres and Notch Therapeutics. Tobias M. Hohl has participated in a scientific advisory board for Boehringer-Ingelheim Inc.
Funding Statement
This work was supported by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) grant RO-5328/2 (T.R.), National Institutes of Health (NIH) grants R01 AI093808 (T.M.H.), R21 AI105617 (T.M.H.), R21 AI156157 (T.M.H.), U01 AI124275 (J.B.X.), R01 AI137269 (J.B.X. and Y.T.), K08 HL143189 (J.U.P.), R01 CA228358 (M.R.M.v.d.B.), R01 CA228308 (M.R.M.v.d.B.), P01 CA023766 (M.R.M.v.d.B.), R01 HL125571 (M.R.M.v.d.B.), R01 HL123340 (M.R.M.v.d.B.), P01 AG052359 (Project 2, M.R.M.v.d.B.), a Takeda Science Foundation-Fellowship (K.Y.M.), an Investigator in the Pathogenesis of Infectious Diseases Award from the Burroughs Wellcome Fund (T.M.H.), the Ludwig Center for Cancer Immunotherapy (T.M.H.), a Tri-Institutional Stem Cell Initiative award 2016-013 (M.R.M.v.d.B.), the Lymphoma Foundation (M.R.M.v.d.B.), the Parker Institute for Cancer Immunotherapy at MSKCC (M.R.M.v.d.B., K.A.M., and J.U.P.), the Susan and Peter Solomon Divisional Genomics Program (T.M.H. and M.R.M.v.d.B.), and the DKMS (K.A.M.). All authors were supported by NIH P30 CA008748 (Cancer Center Core Grant).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The fecal biospecimen repository and this study protocol were approved by the MSKCC institutional review board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All sequence data have been submitted to SRA and will be released upon final acceptance of the manuscript. Requests for clinical data and materials will be reviewed by Memorial Sloan Kettering to determine if they are subject to intellectual property or confidentiality obligations. Data and materials that can be shared will be released via a material transfer or data-sharing agreements.
